

COVID-19 IMPACT

This report has been affected by the COVID-19 pandemic. All forecasts and analysis have been revised to reflect the current view including the effect of the pandemic and associated recession.

RESEARCH REPORT

SYNDROMIC MULTIPLEX DIAGNOSTIC MARKETS with COVID-19 IMPACTS.

Strategies and Trends. Forecasts by Syndrome (Respiratory, Sepsis, GI etc.) by Country. With Market Analysis, Executive Guides and Customization.

2021 to 2025





Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

Table of Contents

- i. Market Guides21
 - iA. Situation Analysis & COVID Impact Overview 22
 - iB. Guide for Executives and Marketing Staff 25
 - iC. Guide for Investment Analysts and Management Consultants..... 27
 - iD. Market Shares of Leading Companies – Table and Chart 28
- 1. Introduction and Market Definition30
 - 1.1 What are Syndromic Multiplex Tests? 31
 - 1.2 Syndromic Testing – the quiet revolution in diagnostics 32
 - 1.2.1 Syndromic Testing – more than Panels. 33
 - 1.3 Market Definition 34
 - 1.3.1 Multiplex Market Size 34
 - 1.3.2 Currency 34
 - 1.3.3 Years 35
 - 1.4 Methodology 36
 - 1.4.1 Authors 36
 - 1.4.2 Sources 36
 - 1.5 U.S. Medical Market and Clinical Laboratory Testing - Perspective..... 37
 - 1.5.1 U.S. Medicare Expenditures for Clinical Testing 38
- 2. The Infectious Diseases – Guide to the Pathogens40
 - 2.0 The Coronavirus 41
 - 2.0.1 Severe acute respiratory syndrome (SARS) 43
 - 2.0.2 Middle East respiratory syndrome (MERS) 45
 - 2.0.3 COVID-19. The SARS CoV 2 Virus..... 46

- 2.0.3.1 Signs and symptoms..... 47
- 2.0.3.2 Transmission..... 48
- 2.0.3.3 Diagnosis 49
- 2.0.3.4 Prevention 51
- 2.0.3.5 Management 52
- 2.0.3.6 Prognosis 53
- 2.0.3.7 New Strains and Subsequent Mutations 54
- 2.1 HIV - Human Immunodeficiency Virus (AIDS) 55
 - 2.1.1 Virology 55
 - 2.1.1.1 Classification 55
 - 2.1.1.2 Structure and genome 56
 - 2.1.1.3 Tropism 58
 - 2.1.1.4 Replication cycle 60
 - 2.1.1.5 Genetic variability 66
 - 2.1.2 Diagnosis 68
 - 2.1.3 Testing..... 69
 - 2.1.3.1 Antibody tests 69
 - 2.1.3.2 Point of Care Tests (POCT) 72
 - 2.1.3.4 Antigen Tests 74
 - 2.1.3.5 Nucleic acid-based tests (NAT)..... 75
 - 2.1.3.6 Other tests used in HIV treatment 76
- 2.2 HBV – Hepatitis B 78
 - 2.2.1 Virology 79
 - 2.2.1.1 Genome..... 80
 - 2.2.1.2 Pathogenesis 81
 - 2.2.1.3 Hepatitis B virus replication 81

- 2.2.1.4 Serotypes and genotypes 82
- 2.2.2 Mechanisms 82
- 2.2.3 Diagnosis 83
- 2.2.4 Market Opportunity Analysis..... 84
- 2.3 HCV – Hepatitis C 86
 - 2.3.1 Taxonomy..... 87
 - 2.3.2.1 Structure 87
 - 2.3.2.2 Genome..... 88
 - 2.3.3 Molecular biology 89
 - 2.3.4 Replication 90
 - 2.3.5 Genotypes 92
 - 2.3.5.1 Clinical importance 92
 - 2.3.6 Market Opportunity Analysis..... 93
- 2.4 HPV - Human papillomavirus 95
 - 2.4.1 Virology 97
 - 2.4.1.1 E6/E7 proteins 97
 - 2.4.1.2 Role in cancer 97
 - 2.4.1.3 E2 research 98
 - 2.4.1.4 Latency period 99
 - 2.4.1.5 Clearance..... 99
 - 2.4.2 Diagnosis 100
 - 2.4.2.1 Cervical testing..... 100
 - 2.4.2.2 Oral testing..... 102
 - 2.4.2.3 Testing men..... 102
 - 2.4.2.4 Other testing 103
 - 2.4.3 Market Opportunity Analysis..... 104

2.5 Influenza 110

 2.5.1 Virology 111

 2.5.1.1 Types of virus 111

 2.5.1.2 Influenzavirus A 111

 2.5.1.3 Influenzavirus B..... 112

 2.5.1.4 Influenzavirus C..... 112

 2.5.1.5 Structure, properties, and subtype nomenclature 113

 2.5.1.6 Replication..... 114

 2.5.2 Testing..... 116

 2.5.2.1 Advantages/Disadvantages of Molecular Assays 118

 2.5.3 Market Opportunity Analysis..... 119

2.6 CTGC - Chlamydia/Gonorhea..... 128

 2.6.1 Gonorrhea 128

 2.6.1.1 Diagnosis 129

 2.6.1.2 Screening 129

 2.6.2 Chlamydia 129

 2.6.2.1 Diagnosis 130

 2.6.2.2 Screening 131

 2.6.3 Testing..... 132

 2.6.3.1 Nucleic acid amplification tests (NAATs). 132

 2.6.3.2 Performance of NAAT Tests 140

 2.6.4 Market Opportunity Analysis..... 141

2.7 Tuberculosis 144

 2.7.1 Mycobacteria..... 145

 2.7.2 Diagnosis 146

 2.7.2.1 Active tuberculosis 146

- 2.7.2.2 Latent tuberculosis 147
- 2.7.3 Epidemiology 147
- 2.7.4 Molecular Diagnostic Tests 149
- 2.7.5 Market Opportunity Analysis..... 150
- 2.8 MRSA - Methicillin-resistant Staphylococcus aureus 152
 - 2.8.1 Diagnosis 152
 - 2.8.2 FDA Approved Molecular Tests 153
 - 2.8.3 Market Opportunity Analysis..... 154
- 2.9 VRE - Vancomycin-resistant Enterococcus 155
 - 2.9.1 FDA Approved MDx Tests for VRE..... 156
 - 2.9.2 Market Opportunity Analysis..... 157
- 2.10 VRE - Vancomycin-resistant Enterococcus 158
 - 2.9.1 FDA Approved MDx Tests for VRE..... 158
 - 2.9.2 Market Opportunity Analysis..... 159
- 3. Industry Overview 161
 - 3.1 Industry Participants 162
 - 3.1.1 IVD Supplier..... 162
 - 3.1.2 Independent lab specialized/esoteric 163
 - 3.1.3 Independent lab national/regional..... 163
 - 3.1.4 Independent lab analytical 164
 - 3.1.5 Public National/regional lab 164
 - 3.1.6 Hospital lab 164
 - 3.1.7 Physician lab 165
 - 3.1.8 Audit body 165
 - 3.2 The Clinical Laboratory Market Segments..... 167
 - 3.2.1 Traditional Market Segmentation..... 167

- 3.2.2 Laboratory Focus and Segmentation..... 168
- 3.2.3 Segmenting the Syndromic Testing Market..... 170
- 3.3 Industry Structure 172
 - 3.3.1 Hospital Testing Share 172
 - 3.3.2 Economies of Scale 172
 - 3.3.2.1 Hospital vs. Central Lab 173
 - 3.3.3 Physician Office Lab's..... 174
 - 3.3.4 Physician's and POCT 174
- 4. Market Trends..... 176
 - 4.1 Factors Driving Growth..... 177
 - 4.1.1 Speed of Diagnosis..... 177
 - 4.1.2 Effect of Syndromic Testing on Costs..... 178
 - 4.1.3 Point of Care Advantage..... 178
 - 4.1.4 Syndrome Testing, Accuracy and Diagnostic Risk..... 178
 - 4.1.5 Single Visits 178
 - 4.1.6 Improvement in Outcomes. 179
 - 4.1.7 Impact of the COVID-19 Pandemic. 179
 - 4.2 Factors Limiting Growth..... 180
 - 4.2.1 Lower Prices 180
 - 4.2.2 Administration/reimbursement..... 181
 - 4.2.3 Infectious Disease is Declining But..... 183
 - 4.2.4 Wellness Hurts..... 183
 - 4.2.5 Economic Growth improves Living Standards 183
 - 4.2.6 Impact of the Pandemic Recession 184
 - 4.3 Instrumentation and Automation..... 185
 - 4.3.1 Instruments Key to Market Share 185

4.3.2 The Shrinking Machine. 185

4.3.3 Syndrome Testing Moving to Big Instruments? 186

4.4 Diagnostic Technology Development 186

4.4.1 Comparing Syndrome and Targeted Testing 187

4.4.2 The Multiplex Paradigm Shift..... 188

4.4.2 The Sepsis Testing Market – Bellwether for Syndromics..... 189

4.4.3 The Single Visit and AntiMicrobial Resistance 189

4.4.4 Syndromics drives POCT adoption 190

4.4.5 A Big Future for PCR? 190

5. Syndromic Testing Recent Developments 192

Recent Developments – Importance and How to Use This Section..... 193

 Importance of These Developments 193

 How to Use This Section 193

Luminex Lands BARDA Grant to Develop Test for SARS-CoV-2, Flu, RSV 193

Molzym, Fraunhofer Developing Rapid Sepsis Diagnostic 194

MiRxes Receives Approval for Multiplex SARS-CoV-2, Flu Test 198

New Approach Involves Silicon-Based Test for Infectious Disease Screening..... 199

Scanogen's Portable Battery Operated Instrument for 90 Minute Multiplex Test 203

Qiagen sees NeuMoDx as Growth Vehicle..... 206

Torus Biosystems Developing Syndromic Test with 30-Minute Turnaround 210

Roche, Speedx Partner to Expand Access to Antibiotic Resistance Tests..... 214

BioMérieux's BioFire SARS-CoV-2 Respiratory Panel Wins FDA EAU 215

Infectious Disease Testing Firm Curative Acquires KorvaLabs 215

ChromaCode Raises Additional \$10M 216

COVID-19 Patients Need Syndromic Testing 217

GenMark Diagnostics – New Respiratory Panel due in June 218

Qiagen Respiratory Panel with Coronavirus Targets Receives CE Mark 220
 Exact Diagnostics launches respiratory panel control 221
 bioMérieux submits enhanced BIOFIRE® BCID2 Panel to FDA 221
 Nanomix Receives CE Mark for Diagnostic 223
 Applied BioCode Applies to FDA for Syndromic Respiratory Panel 224
 Expedeon AG and Sona Nanotech to Collaborate on Multiplex POC 225
 QIAGEN's New GI Panel Performance Assessed 226
 McKesson to Distribute QIAstat-Dx Syndromic Testing Solution in USA 227
 Applied BioCode Obtains FDA Clearance 228
 Meridian Bioscience to Acquire GenePOC Inc 229
 Curetis Introduces Rapid DNA Testing for Antibiotic Resistance 230
 Qiagen gets FDA clearance for syndromic testing system 231
 Entasis Therapeutics Signs Rapid Diagnostic Agreement with bioMérieux 232
 Akonni Biosystems Submits Multiplex Diagnostics System to FDA 233
 Ador Diagnostic to receive \$30M in Funding for 100-Plex PoC 234
 SAW Diagnostics Receives Funding for Commercialisation of PoC Platform 235
 QuantuMDx and Molbio announce MoU 237
 Immunexpress Wins \$745K Contract for Rapid Sepsis Assay 238
 Mobidiag Inks European, Middle Eastern Distribution Deals 239
 BIOFIRE® FILMARRAY® System chosen for Phase 3 clinical trial 240
 5.1 Profiles of Key Syndromic Testing Companies 241
 Abacus Diagnostica 242
 Abbott Diagnostics 243
 Accelerate Diagnostics 245
 Ador Diagnostics 246
 Akonni Biosystems 247

Alveo Technologies..... 248

Applied BioCode..... 249

Aus Diagnostics 250

Beckman Coulter Diagnostics..... 251

Becton, Dickinson and Company 252

Binx Health 254

Biocartis 255

bioMérieux Diagnostics..... 256

Bio-Rad Laboratories, Inc. 259

Bosch Healthcare Solutions GmbH..... 261

Cepheid (now Danaher) 262

Credo Diagnostics Biomedical 263

Cue Health..... 264

Curetis N.V. / Curetis GmbH 265

Diagenode Diagnostics 266

Diasorin S.p.A..... 267

Enzo Life Sciences, Inc. 268

Eurofins Scientific 269

Fluxergy 271

Fusion Genomics 272

Genetic Signatures..... 274

GenMark Dx..... 275

Hibergene Diagnostics 277

Hologic 278

Immunexpress..... 280

Inflammatix 281

Invetech..... 282

Janssen Diagnostics 283

Karius 284

Lexogene 285

LightDeck Diagnostics 286

Luminex Corp 287

Maxim Biomedical 288

Meridian Bioscience..... 289

Mesa Biotech..... 290

Millipore Sigma 291

Mobidiag 292

Nanomix..... 293

Operon..... 294

Oxford Nanopore Technologies 295

Panagene 296

Perkin Elmer..... 297

Primerdesign 298

Prominex 299

Qiagen Gmbh 300

Quantumdx 302

Quidel..... 303

Roche Molecular Diagnostics 304

Saw Diagnostics 306

Seegene 307

Siemens Healthineers 308

Sona Nanotech..... 311

SpeeDx..... 312

T2 Biosystems..... 313

Thermo Fisher Scientific Inc..... 314

Veramarx 317

XCR Diagnostics 318

6. The Global Market for Syndromic Multiplex Diagnostics319

6.1 Global Market Overview by Country..... 320

6.1.1 Table – Global Market by Country..... 320

6.1.2 Chart - Global Market by Country 321

6.2 Global Market by Syndrome - Overview 322

6.2.1 Table – Global Market by Syndrome 322

6.2.2 Chart – Global Market by Syndrome – Base/Final Year Comparison 323

6.2.3 Chart – Global Market by Syndrome – Base Year 324

6.2.4 Chart – Global Market by Syndrome – End Year..... 325

6.2.5 Chart – Global Market by Syndrome – Share by Year 326

6.2.6 Chart – Global Market by Syndrome – Segments Growth..... 327

6.3 Global Market by Place - Overview 328

6.3.1 Table – Global Market by Place..... 328

6.3.2 Chart – Global Market by Place – Base/Final Year Comparison 329

6.3.3 Chart – Global Market by Place – Base Year..... 330

6.3.4 Chart – Global Market by Place – End Year 331

6.3.5 Chart – Global Market by Place – Share by Year..... 332

6.3.6 Chart – Global Market by Place – Segments Growth 333

7. Global Syndromic Multiplex Markets – By Syndrome334

7.1 Respiratory 335

7.1.1 Table Respiratory – by Country 335

7.1.2 Chart - Respiratory Growth..... 336

7.2 Gastrointestinal..... 337

7.2.1 Table Gastrointestinal – by Country 337

7.2.2 Chart - Gastrointestinal Growth 338

7.3 Blood..... 339

7.3.1 Table Blood – by Country 339

7.3.2 Chart - Blood Growth 340

7.4 Meningitis/Encephalitis..... 341

7.4.1 Table Meningitis/Encephalitis – by Country..... 341

7.4.2 Chart - Meningitis/Encephalitis Growth 342

7.5 Sexually Transmitted Disease 343

7.5.1 Table Sexually Transmitted Disease – by Country 343

7.5.2 Chart – Sexually Transmitted Disease Growth..... 344

7.6 Other..... 345

7.6.1 Table Other – by Country 345

7.6.2 Chart - Other Growth..... 346

8. Global MDx Infectious Disease Markets – by Place 347

8.1 Hospital Lab 348

8.1.1 Table Hospital Lab – by Country 348

8.1.2 Chart - Hospital Lab Growth..... 349

8.2 Outpatient Lab 350

8.2.1 Table Outpatient Lab – by Country 350

8.2.2 Chart - Outpatient Lab Growth 351

8.3 POC 352

8.3.1 Table POC – by Country 352

8.3.2 Chart - POC Growth..... 353

8.4 Other Technology..... 354

 8.4.1 Table Other – by Country 354

 8.4.2 Chart - Other Growth..... 355

Appendices356

 I. United States Medicare System: 2021 Clinical Laboratory Fees Schedule 356

Table of Tables

Table 1 Market Share of Leading Companies 28

Table 2 Medicare Clinical Lab Expenditures Actual & Forecast 2014 to 2024 (\$Billion) 39

Table 3 Characteristics of Coronavirus Pandemic Infections 46

Table 4 COVID-19 Symptoms..... 48

Table 5 Classification of HIV Species..... 56

Table 6 HBV Tests - CMS Codes & Prices 86

Table 7 HCV Tests - CMS Codes & Prices 93

Table 8 HPV Clearance Rates 100

Table 9 HPV Tests - CMS Codes & Prices 105

Table 10 HPV Tests, Technology, Types 106

Table 11 Types of Influenza Tests 116

Table 12 Influenza Tests - CMS Codes & Prices..... 119

Table 13 FDA Cleared Molecular Assays for Influenza 121

Table 14 FDA Cleared NAAT CTGC Tests 133

Table 15 CTGC NAAT Target Sequences and Possible False Reactions 138

Table 16 Influenza Tests - CMS Codes & Prices..... 142

Table 17 FDA Approved MDx Tests for Tuberculosis 149

Table 18 Tuberculosis Tests - CMS Codes & Prices..... 150

Table 19 FDA Approved Tests for MRSA 153

Table 20 MRSA Tests - CMS Codes & Prices 155

Table 21 FDA Approved Tests for VRE 156

Table 22 VRE Tests - CMS Codes & Prices 157

Table 23 FDA Approved Tests for VRE 158

Table 24 VRE Tests - CMS Codes & Prices 160

Table 25 Market Players by Type 162

Table 26 Clinical Laboratory Departments and Segments 167

Table 27 Laboratory Management Focus – Different Approaches 168

Table 28 Key Segmentation Variables Going Forward..... 170

Table 29 Possible Market Segments of Syndromic Multiplex Market 170

Table 30 Five Factors Driving Growth 177

Table 31 How SMT Improves Outcomes..... 179

Table 32 Four Factors Limiting Growth 180

Table 33 - Global Market by Region 320

Table 34 Global Market by Syndrome 322

Table 35 Global Market by Place..... 328

Table 36 Respiratory by Country..... 335

Table 37 Gastrointestinal by Country 337

Table 38 Blood by Country..... 339

Table 39 Meningitis/Encephalitis by Country 341

Table 40 Sexually Transmitted Disease by Country 343

Table 41 Other by Country..... 345

Table 42 Hospital Lab by Country 348

Table 43 Outpatient Lab by Country 350

Table 44 POC by Country 352

Table 45 Other by Country..... 354

Table 46 2021 Clinical Lab Fee Schedule 356

Table of Figures

Figure 1 Market Share of Leading Companies Chart 29

Figure 2 Medicare Clinical Lab Expenditures 2014 to 2024 (\$Million) 38

FIGURE 3 STRUCTURE OF CORONAVIRUSES 42

Figure 4 HIV Virion 57

Figure 5 Diagram of the HIV Replication Cycle 61

Figure 6 The Structure of the HBV Virus..... 80

Figure 7 Hepatitis B Replication 81

Figure 8 Structure of the HCV Virus..... 88

Figure 9 HCV Replication Cycle 91

Figure 10 Structure of the Influenza Virion 113

Figure 11 Influenza Replication..... 114

Figure 12 Scanning Electronmicrograph of Tuberculosis..... 145

Figure 13 Chart Death Rates and Infectious Disease Decline 182

Figure 14 Comparing Syndromic and Targeted Testing..... 187

Figure 15 The Multiplex Paradigm Shift..... 188

Figure 16 Global Market Share Chart 321

Figure 17 Global Market by Syndrome - Base vs. Final 323

Figure 18 Global Market by Syndrome Base Year 324

Figure 19 Global Market by Syndrome End Year 325

Figure 20 Syndrome Share by Year 326

Figure 21 Syndrome Segments Growth..... 327

Figure 22 Global Market by Place - Base vs. Final..... 329

Figure 23 Global Market by Place Base Year..... 330

Figure 24 Global Market by Place End Year 331

Figure 25 Place Share by Year..... 332

Figure 26 Place Segments Growth 333

Figure 27 Respiratory Growth..... 336

Figure 28 Gastrointestinal Diagnostics Growth..... 338

Figure 29 Blood Growth..... 340

Figure 30 Meningitis/Encephalitis Growth 342

Figure 31 Sexually Transmitted Disease Growth 344

Figure 32 Other Growth..... 346

Figure 33 Hospital Lab Growth..... 349

Figure 34 Outpatient Lab Growth 351

Figure 35 POC Growth..... 353

Figure 36 Other Growth..... 355